DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. ...

On Tuesday, DexCom Inc (DXCM) stock saw a decline, ending the day at $67.1 which represents a decrease of $-2.08 or -3.01% from the prior close of $69.18. The stock opened at $69 and touched a low of ...

Investors and analysts reacted immediately to DexCom's revelation. The price of DexCom's common stock declined dramatically.

A top healthcare stock to own over the years has been DexCom (DXCM 1.18%). The company makes continuous glucose monitors ...

We recently made a list of Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks. In this piece, we will look at where ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been filed ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

We take another look at Dexcom, as the reimbursement environment has brightened, new diabetes patient pools offer upside, and the firm has amped up its innovation. The bottom line: After a lengthy ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION ...

Artisan Mid Cap Fund highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the third quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that engages in the ...